Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity

NACompletedINTERVENTIONAL
Enrollment

911

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

August 29, 2022

Study Completion Date

August 29, 2022

Conditions
Newborn Vaccine Immunogenicity
Interventions
BIOLOGICAL

Hepatitis B vaccine (HBV)

Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.

BIOLOGICAL

Bacillus Calmette-Guérin (BCG)

Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.

Trial Locations (2)

Unknown

Institute for Medical Research, Goroka

000273

Medical Research Council Unit, The Gambia, Fajara

All Listed Sponsors
collaborator

Medical Research Council Unit, The Gambia

OTHER

collaborator

University of British Columbia

OTHER

collaborator

Institute for Medical Research, Papua New Guinea

UNKNOWN

collaborator

The University of Western Australia

OTHER

lead

Boston Children's Hospital

OTHER

NCT03246230 - Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity | Biotech Hunter | Biotech Hunter